1. Home
  2. BFRI

as 06-12-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Founded: 1997 Country:
United States
United States
Employees: N/A City: WOBURN
Market Cap: 5.5M IPO Year: 2021
Target Price: $18.00 AVG Volume (30 days): 98.7K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -10.20 EPS Growth: N/A
52 Week Low/High: $0.61 - $13.42 Next Earning Date: 05-15-2024
Revenue: $33,252,000 Revenue Growth: 20.23%
Revenue Growth (this year): 21.96% Revenue Growth (next year): 25.35%

BFRI Daily Stock ML Predictions

Share on Social Networks: